News | January 02, 2025
Innovent inks agreement with Roche for Novel DLL3 ADC
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging
Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)
Subscribe To Our Newsletter & Stay Updated
